B7-1

B7-1 Overview

English NameCluster of differentiation 80Approved Drugs2
Drugs in Clinical Trials10Target SynonymActivation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimulatory Factor CD80,CD80 Antigen,B7-1,B7.1,B7-1 Antigen,B7,CD80,CD28LG
Highest Development StageApproved
English NameCluster of differentiation 80
Target SynonymActivation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimulatory Factor CD80,CD80 Antigen,B7-1,B7.1,B7-1 Antigen,B7,CD80,CD28LG
Approved Drugs2
Drugs in Clinical Trials10
Highest Development StageApproved

B7-1 Background

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 Synonyms

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ORCA-010ORCA-010Phase 2 ClinicalOrca Therapeutics BvProstatic Neoplasms
Details
CED-88004SCED-88004SCED-88004S; CED-88004-S; 89ZED88082APhase 2 ClinicalUmcg The University Medical Center GroningenLymphoma, B-Cell
Details
Membrane bound ligand T-SIGn virusNG-348Phase 1 ClinicalAkamis Bio LtdNeoplasms
Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)Z-CTLsPhase 1 ClinicalHunan Zhaotai Yongren Biotech Co LtdCarcinoma, Non-Small-Cell Lung
Details
JLM-019JLM-019Phase 1 ClinicalJecho Biopharmaceuticals Co LtdLymphoma; Solid tumours
Details
M-5542M5542; M-5542Phase 1 ClinicalMerck & Co Inc
Details
Abatacept biosimilar (Kashiv BioSciences)KSHB-002; KSHB002Phase 1 ClinicalKashiv BioSciences LLCArthritis, Rheumatoid; Immune System Diseases
Details
Abatacept biosimilar (Dr. Reddy's Laboratories)DRL-ABPhase 1 ClinicalDr.Reddy's Laboratories LtdArthritis, Rheumatoid
Details
SG-1827SG1827; SG-1827Phase 1 ClinicalHangzhou Shangjian Biotechnology Co LtdSolid tumours
Details
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio)VDJ002; VDJ-002Phase 1 ClinicalBeijing Vdjbio Co LtdArthritis, Rheumatoid; Lupus Erythematosus, Systemic
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
BelataceptLEA29Y; LEA-029; BMS-224818; L104EA29YIgApprovedBristol-Myers Squibb CompanyNulojixUnited StatesRejection of renal transplantationBristol-Myers Squibb Company2011-06-15Arthritis, Rheumatoid; Delayed Graft Function; Diabetes Mellitus, Type 1; Graft Rejection; Kidney Failure, Chronic; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection in heart transplantation; Rejection of renal transplantation; Rejection of organ transplantation
Details
AbataceptBMS-188667; ONO-4164; ONO-4164SC; BMS-188667SCApprovedBristol-Myers Squibb CompanyOrencia, 恩瑞舒United StatesArthritis, RheumatoidBristol-Myers Squibb Company2005-12-23Allergic asthma; Alopecia Areata; Anemia, Aplastic; Anemia, Diamond-Blackfan; Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthralgia; Arthritis; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Behcet Syndrome; beta-Thalassemia; Cardiovascular Diseases; Chediak-Higashi Syndrome; Colitis, Ulcerative; Common Variable Immunodeficiency; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Dermatomyositis; Diabetes Mellitus, Type 1; Dyskeratosis Congenita; Eye Diseases; Fanconi Anemia; Giant Cell Arteritis; Glomerulosclerosis, Focal Segmental; Graft vs Host Disease; Granulomatosis with Polyangiitis; Granulomatous Disease, Chronic; Healthy Aging; Hematologic Diseases; Hematologic Neoplasms; Immunoglobulin G4-Related Disease; Inflammation; Kostmann Syndrome; Leukocyte-Adhesion Deficiency Syndrome; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphohistiocytosis, Hemophagocytic; Mucopolysaccharidosis I; Multiple Sclerosis; Multiple S
Details

Product Reviews

  • 1***22019-10-12
    0People Like
    I purchased this protein for ELISA experiment. I coated CD80 protein into the well plate, and then mixed the antibody molecule and the biotin-PDL1 protein for a blocking assay. I could obtain ideal data.
  • Overview
  • Product List
  • Marketed Drug Information
  • Product Reviews
  • Clinical Drug Information